GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » ROC %

VIA Pharmaceuticals (VIA Pharmaceuticals) ROC % : -26.59% (As of Dec. 2010)


View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. VIA Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Dec. 2010 was -26.59%.

As of today (2024-06-21), VIA Pharmaceuticals's WACC % is 0.00%. VIA Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). VIA Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


VIA Pharmaceuticals ROC % Historical Data

The historical data trend for VIA Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIA Pharmaceuticals ROC % Chart

VIA Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -188.00 -411.94 -5,335.33 -251.55 -48.75

VIA Pharmaceuticals Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -116.06 -92.39 -50.00 -40.32 -26.59

VIA Pharmaceuticals ROC % Calculation

VIA Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2010 is calculated as:

ROC % (A: Dec. 2010 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2009 ) + Invested Capital (A: Dec. 2010 ))/ count )
=-5.914 * ( 1 - 0% )/( (10.206 + 14.057)/ 2 )
=-5.914/12.1315
=-48.75 %

where

VIA Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2010 is calculated as:

ROC % (Q: Dec. 2010 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2010 ) + Invested Capital (Q: Dec. 2010 ))/ count )
=-3.54 * ( 1 - 0% )/( (12.572 + 14.057)/ 2 )
=-3.54/13.3145
=-26.59 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2010) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VIA Pharmaceuticals  (GREY:VIAP) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, VIA Pharmaceuticals's WACC % is 0.00%. VIA Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). VIA Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


VIA Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
750 Battery Street, Suite 330, San Francisco, CA, USA, 94111
VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.
Executives
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p. 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp 10 percent owner 750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright officer: V.P. ? Finance, Controller 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen director, officer: CEO and President 750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson director 14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub officer: SVP, Research & Development 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun officer: Chief Medical Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd 10 percent owner, other: Possible Member of 10% Group BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus